Post

New research · Obstetrics & Gynecology
Molecular and clinical oncology · 1w
Cohort studyMolecular and clinical oncology · 2026

Low-grade serous ovarian cancer in Indonesia: Insights from the largest multicenter cohort in a middle-income country.

Brahmana Askandar Tjokroprawiro, Khoirunnisa Novitasari, Wita Saraswati … Eccita Rahestyningtyas
Read paper
Obstetrics & GynecologyCohort study

Residual disease after surgery was the strongest independent predictor of death in low-grade serous ovarian cancer

Low-grade serous ovarian cancer in Indonesia: Insights from the largest multicenter cohort in a middle-income country.

Brahmana Askandar Tjokroprawiro … Eccita Rahestyningtyas
Molecular and clinical oncology · 2026
Background

Low-grade serous ovarian cancer (low-grade serous ovarian cancer), a rare subtype of epithelial ovarian cancer, is characterized by indolent growth and limited chemosensitivity.

Purpose

The present study aimed to describe the clinical and pathological characteristics of patients with low-grade serous ovarian cancer in Indonesia.

Methods

Of the cohort, ~50% presented with advanced-stage disease (International Federation of Gynecology and Obstetrics III-IV, 50%).

n = 160 patients
5.59
Results
5.59
Leftover tumour after surgery was linked to a 5.59-fold higher death rate (adjusted HR)
n = 160 patients
More results

Ascites and elevated cancer antigen-125 levels were observed in 43.1 and 70.6% of patients, respectively.

The overall recurrence rate was 10, and 92.5% of patients were alive at the last follow-up.

Kaplan-Meier analysis showed worse survival in patients with advanced-stage disease and residual disease.

More results

In univariate Cox regression, residual disease (HR, 7.93) and recurrence (HR, 10.06) showed the strongest associations with mortality.

“
Conclusion

In this multicenter cohort, residual disease was the key determinant of survival, underscoring the importance of complete cytoreductive surgery and early diagnosis.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Randomized Trial
hazard ratio 0.43
cancer was much less likely to grow or come back during follow-up
Randomized Trial
2.52%
similarly low rate of cancer returning in the pelvis after simpler, less extensive surgery
Study
120
essential learning goals international experts agreed every global surgery training program should cover
Cohort Study
HR 0.85
The hazard of death was similar with adjuvant chemoradiotherapy versus radiotherapy alone.
Randomized Trial
HR 0·42
for p53-abnormal tumors, combined treatment nearly halved the risk of cancer returning
Randomized Trial
-2.3 percentage points
the chance of staying cancer-free for 3 years was higher with biopsy only
Study
96.2% (90% CI, 85.9%-97.9%)
high percentage of patients whose hormone levels returned to normal, allowing treatment to stop
Cohort Study
33.3%
Among pregnant women with anemia, a higher percentage had babies born early